Ubs Group Ag Protagonist Therapeutics, Inc Transaction History

Ubs Group Ag

$452 Billion
Q3 2024

A detailed history of Ubs Group Ag transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Ubs Group Ag holds 78,799 shares of PTGX stock, worth $3.53 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

78,799

Previous 66,981 17.64%

Holding current value

$3.53 Million

Previous $2.32 Million 52.63%

% of portfolio

0.0%

Previous 0.0%

31 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$33.72 - $47.33 $398,502 - $559,345	11,818 Added 17.64%	78,799 $3.54 Million
Q2 2024 Aug 13, 2024	SELL	$24.66 - $34.8 $2.73 Million - $3.85 Million	-110,565 Reduced 62.27%	66,981 $2.32 Million
Q1 2024 May 13, 2024	BUY	$21.79 - $32.15 $581,335 - $857,729	26,679 Added 17.68%	177,546 $5.14 Million
Q4 2023 Feb 09, 2024	BUY	$14.05 - $23.44 $844,981 - $1.41 Million	60,141 Added 66.29%	150,867 $3.46 Million
Q3 2023 Nov 09, 2023	BUY	$16.68 - $23.66 $420,102 - $595,900	25,186 Added 38.43%	90,726 $1.51 Million
Q2 2023 Aug 11, 2023	SELL	$18.02 - $29.36 $908,189 - $1.48 Million	-50,399 Reduced 43.47%	65,540 $1.81 Million
Q1 2023 May 12, 2023	SELL	$10.78 - $25.38 $1.18 Million - $2.78 Million	-109,590 Reduced 48.59%	115,939 $2.67 Million
Q4 2022 Feb 08, 2023	BUY	$7.36 - $11.17 $1.32 Million - $2 Million	178,949 Added 384.18%	225,529 $2.46 Million
Q3 2022 Nov 10, 2022	SELL	$7.86 - $11.71 $647,719 - $964,985	-82,407 Reduced 63.89%	46,580 $393,000
Q2 2022 Aug 10, 2022	BUY	$7.06 - $25.52 $43,927 - $158,785	6,222 Added 5.07%	128,987 $1.02 Million
Q1 2022 May 16, 2022	BUY	$23.34 - $36.08 $1.32 Million - $2.04 Million	56,454 Added 85.14%	122,765 $2.91 Million
Q4 2021 Feb 14, 2022	SELL	$17.63 - $37.1 $51,197 - $107,738	-2,904 Reduced 4.2%	66,311 $2.27 Million
Q3 2021 Nov 15, 2021	BUY	$12.95 - $49.69 $861,744 - $3.31 Million	66,544 Added 2491.35%	69,215 $1.23 Million
Q2 2021 Aug 13, 2021	SELL	$25.57 - $44.88 $1.07 Million - $1.88 Million	-41,902 Reduced 94.01%	2,671 $120,000
Q1 2021 May 12, 2021	SELL	$19.02 - $31.15 $387,247 - $634,214	-20,360 Reduced 31.36%	44,573 $1.15 Million
Q4 2020 Feb 11, 2021	BUY	$18.49 - $25.13 $193,128 - $262,482	10,445 Added 19.17%	64,933 $1.31 Million
Q3 2020 Nov 12, 2020	SELL	$15.19 - $22.4 $215,682 - $318,057	-14,199 Reduced 20.67%	54,488 $1.07 Million
Q2 2020 Jul 31, 2020	SELL	$6.19 - $18.84 $28,139 - $85,646	-4,546 Reduced 6.21%	68,687 $1.21 Million
Q1 2020 May 01, 2020	BUY	$5.4 - $9.22 $281,199 - $480,122	52,074 Added 246.11%	73,233 $517,000
Q4 2019 Feb 14, 2020	BUY	$4.69 - $13.45 $21,292 - $61,063	4,540 Added 27.32%	21,159 $149,000
Q3 2019 Nov 14, 2019	SELL	$9.41 - $16.56 $824,146 - $1.45 Million	-87,582 Reduced 84.05%	16,619 $200,000
Q2 2019 Aug 14, 2019	BUY	$8.98 - $12.96 $920,952 - $1.33 Million	102,556 Added 6234.41%	104,201 $1.26 Million
Q1 2019 May 14, 2019	SELL	$6.5 - $13.77 $1,417 - $3,001	-218 Reduced 11.7%	1,645 $21,000
Q4 2018 Feb 14, 2019	SELL	$6.3 - $10.44 $32,709 - $54,204	-5,192 Reduced 73.59%	1,863 $12,000
Q3 2018 Nov 14, 2018	SELL	$6.82 - $11.26 $231,511 - $382,231	-33,946 Reduced 82.79%	7,055 $73,000
Q2 2018 Aug 14, 2018	BUY	$5.99 - $9.1 $245,595 - $373,109	41,001 New	41,001 $276,000
Q1 2018 May 15, 2018	SELL	$8.46 - $23.08 $3,282 - $8,955	-388 Closed	0 $0
Q4 2017 Feb 14, 2018	BUY	$14.47 - $20.8 $1,143 - $1,643	79 Added 25.57%	388 $8,000
Q3 2017 Nov 14, 2017	SELL	$10.61 - $17.98 $14,450 - $24,488	-1,362 Reduced 81.51%	309 $5,000
Q2 2017 Aug 14, 2017	BUY	N/A	1,342 Added 407.9%	1,671 $19,000
Q1 2017 Nov 14, 2017	BUY	N/A	329	329 $4,000

Others Institutions Holding PTGX

# of Institutions

247

Shares Held

56.4M

Call Options Held

76.3K

Put Options Held

114K

View Full List

About Protagonist Therapeutics, Inc

Ticker PTGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,084,100
Market Cap $2.2B
Description
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...

More about PTGX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account